A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...

What a brutal six months it’s been for DexCom. The stock has dropped 32.6% and now trades at $58.63, rattling many ...

DexCom receives FDA clearance for DexCom Smart Basal titration software module, which optimizes basal insulin dose in type 2 ...

DexCom (NASDAQ:DXCM) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their recent ratings, ...

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

These healthcare stocks have long-term and profitable growth runways.

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

A software defect could cause the app to terminate, resulting in missed alerts or alarms. Dexcom required users to update the app.

Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...